Averhealth’s COVID-19 Action Plan
Averhealth’s COVID-19 Action Plan
  • Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Averhealth logo

Averhealth

Substance use monitoring and treatment solutions.

  • Solutions
    • Aversys
    • Service Levels
  • Programs
    • Pretrial, Probation, and Parole
    • Treatment Courts
    • Child and Family Services
    • Providers
    • Payers
    • Clients
  • Why Averhealth
    • Our Laboratory
  • Blog
  • Resources
    • Media Room
    • Education
    • White Papers
    • Webinars
    • Newsletters
  • About
    • Leadership
    • Careers
    • Job Openings
    • Certifications & Licenses
    • Our Partners
    • Events
    • Contact
    • Locations
  • Log In
    • Provider
    • Patient

Newsletter Archive

DECEMBER 2020

  • Struggling with SUD for the Holidays
  • Drug Trends: VapesComing Soon: APPA Webinar
  • APPA Webinar – Presented by Douglas B. Marlowe, J.D., Ph.D.
  • In Memoriam: The Honorable Ruben Reyes
READ NEWSLETTER

NOVEMBER 2020

Girl dealing with the stress and loneliness of addiction during COVID-19.
  • Dealing with the Addiction Crisis During the Nightmare of COVID-19
  • Drug Trends: Marijuana Concentrates
  • Coming Soon: APPA Webinar
  • Rising Stimulant Deaths Show that We Face More than Just an Opioid Crisis
  • Kentucky seeks to be first in the nation to treat substance use disorder in prisons using Medicaid dollars
READ NEWSLETTER

OCTOBER 2020

  • Drug and Alcohol Testing in Community Corrections: Some Provocative Findings
  • NADCP Webinar featuring Maricopa County
  • NADCP Congratulates Federal Grant Award Recipients
  • Indiana University Researcher Helping At-Risk Students Steer Away from Substance Use Disorder
  • DEA Pressured to Create a Telehealth Registration for Drug Abuse Treatment
READ NEWSLETTER

SEPTEMBER 2020

  • Evidence-Based Practices for Substance Use Disorder Testing
  • Drug Trends: Marijuana
  • Substance use disorder impacts a whole family
  • Look beyond opioids to solve national substance use epidemic
  • Substance use disorders linked to COVID-19 susceptibility
READ NEWSLETTER

AUGUST 2020

The Impact of SUD and Mental Health on Healthcare Costs
  • The Impact of SUD and Mental Health on Healthcare Costs
  • Customer Testimonial
  • Drug Trends: Kratom
  • St. Charles County Treatment Court Celebrates 20 Years of Providing Second Chances
  • COVID-19 and the opioid crisis: When a pandemic and an epidemic collide
  • Shatterproof launches free addiction treatment locator tool with backing from Aetna, Anthem, Cigna and UnitedHealth
READ NEWSLETTER

JULY 2020

Drug Testing during COVID-19 requires Averhealth employees to wear PPE
  • 5 Solutions for Drug Testing during COVID-19
  • Customer Testimonial
  • How Bangor Drug Court participants are getting help staying sober during the pandemic
  • The Significance of Vermont’s Justice Reinvestment Legislation
  • Pretrial, Probation, and Parole Supervision Week
READ NEWSLETTER

JUNE 2020

  • Averhealth’s Testing Solutions During a Crisis
  • Chester County Drug Court Continues Testing
  • Averhealth’s Webinar
  • Averhealth — Proud Platinum Sponsor of NADCP All RISE20 Virtual
  • COVID-19 is Causing People to Relapse
  • 75,000 Americans at risk of dying from overdose or suicide due to coronavirus despair, group warns
  • Returning to resilience: The impact of COVID-19 on mental health and substance use
READ NEWSLETTER

Primary Sidebar

BLOG SEARCH

Join Our Newsletter

Be the first to find out when we have exclusive news, articles or upcoming events to share.

Footer

  • Facebook
  • LinkedIn
 
866. 680. 3106
info@Averhealth.com

Newsletter Signup

Averhealth, Avertest, Aversys, and the associated logos and all associated marks are registered trademarks or service marks of Avertest, LLC. © 2021 Avertest, LLC. All rights reserved.

  • Lab Certifications
  • Non-Discrimination Notice
  • Compliance
  • texas Department of information resources
  • SAM registration